Atezolizumab monotherapy has been reimbursed in Israel since January 2020 for 2L treatment after PBC, and since January 2021 for 1L treatment of mNSCLC as monotherapy for patients with high PD-L1 expression (≥50%) and in combination with chemotherapy regardless of PD-L1 expression level based on the Impower110 study (25, 26). Here, CD274 is linked to primary biliary cholangitis.